Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Saturday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of Aptose Biosciences in a research report on Tuesday, December 3rd.

Aptose Biosciences Trading Up 3.9 %

APTO stock opened at $0.20 on Friday. The firm’s 50-day moving average is $0.33 and its two-hundred day moving average is $0.52. The company has a market capitalization of $12.05 million, a price-to-earnings ratio of -0.07 and a beta of 1.07. Aptose Biosciences has a 52 week low of $0.13 and a 52 week high of $2.82.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.